Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned - Sophion

Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned


Author(s): Ryan Choi, Matthew A. Hulverson, Wenlin Huang, Rama S.R. Vidadala, Grant R.Whitman, Lynn K.Barrett, Deborah A. Schaefer, Dana P.Betzer, Michael W. Riggs, J. Stone Doggett, Andrew Hemphill, Luis Miguel Ortega-Morag Molly C. McCloskey, Samuel L.M. Arnold, Robert C.Hackmanhi, Kennan C.Marsh, James J. Lynch, Gail M. Freiberg, Bruce E. Leroy, Dale J.Kempf, Robert K.M.Choy, Eugenio L .de Hostos, Dustin J.Maly, Erkang Fan, Kayode K. Ojo, Wesley C. Van Voorhis


Bumped Kinase Inhibitors, targeting Calcium-dependent Protein Kinase 1 in apicomplexan parasites with a glycine gatekeeper, are promising new therapeutics for apicomplexan diseases. Here we will review advances, as well as challenges and lessons learned regarding efficacy, safety, and pharmacology that have shaped our selection of pre-clinical candidates.

Contact

Contact Sophion

Sophion Bioscience A/S
Baltorpvej 154, 2750 Ballerup, Denmark
Telephone: +45 44 60 88 00

You need to fill in all required fields.

When opting-in for our newsletter you will receive 4-6 newsletters per year. You can always opt-out directly from the newsletters. For more information see our privacy policy